Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Schopohl

Showing results (81-90 of 83) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 83 results.
The Journal of Clinical Endocrinology and Metabolism|April 23, 2010
Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trialS Petersenn, J Schopohl, A Barkan, et al.
Pituitary|August 15, 2013
Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II studyM Boscaro, J Bertherat, J Findling, et al.
Clinical Endocrinology|December 7, 2000
Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegalyP Chanson, V Boerlin, C Ajzenberg, et al.
Pageof 9

Showing results (81-90 of 83) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 83 results.
The Journal of Clinical Endocrinology and Metabolism|April 23, 2010
Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trialS Petersenn, J Schopohl, A Barkan, et al.
Pituitary|August 15, 2013
Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II studyM Boscaro, J Bertherat, J Findling, et al.
Clinical Endocrinology|December 7, 2000
Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegalyP Chanson, V Boerlin, C Ajzenberg, et al.
Pageof 9